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Abstract: The prognostic significance of human papillomavirus (HPV) DNA and E6/E7 mRNA, the presence of specific 
types, and the physical state of HPV DNA, were studied in 202 cervical squamous cell carcinomas. Absence or non-
detectable levels of high-risk (types 16, 18, 31, 33, 35, 45, 52 and 58) E6/E7 mRNA, using the real-time nucleic acid se-
quence based amplification (NASBA) assay, and absence of HPV high-risk/HPV 6, 26, 66, 69, 73 (all methods collec-
tively) were associated with poor overall survival in univariate analysis (P = 0.04 and P = 0.03, respectively) and had in-
dependent prognostic value in multivariate analysis (P = 0.01 and P = 0.03, respectively) including FIGO stage and age. 
Based on the individual results of type-specific PCR and in situ hybridization (ISH), the presence of HPV DNA was not 
found to be a prognostic factor. Likewise, concerning the presence of specific HPV types and the HPV integration status 
(determined by ISH), no prognostic significance was found. Mutation analyses of the TP53 gene revealed mutations in 3 
of the 6 HPV negative samples (50%). 
INTRODUCTION 
  Human papillomavirus (HPV) is known to be a major 
risk factor in the development of cervical cancer [1]. How-
ever, the role of HPV for the clinical outcome of cervical 
carcinomas is debatable. Previous studies have reported 
various results on whether the presence of HPV, and also 
whether the presence of a specific type over another, may 
have prognostic value for the clinical outcome of women 
with cervical cancer. Some studies have reported that pa-
tients with HPV negative cervical tumours have a worse 
prognosis than those with HPV positive tumours [2-6]; other 
studies have found the presence of HPV to be unrelated to 
clinical outcome [7-10]. In most of these studies, HPV DNA 
was detected by PCR [2, 4, 5, 9-16] or in situ hybridization 
(ISH) [3, 6, 7]. When it comes to different HPV genotypes, 
we do know that different types have different oncogenic 
potential in causing cervical cancer. The question is however 
whether these also may exert different pressure in terms of  
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the clinical outcome of women with cervical cancer. In pre-
vious studies, a reduced survival has in particular been corre-
lated with HPV 18 positive tumours [11-15]. Reduced sur-
vival has also been demonstrated for women with multiple 
HPV types [16]. Nevertheless, no definite conclusions re-
garding a different impact of different types on clinical out-
come have been disclosed. 
  The presence of HPV E6/E7 oncoproteins is crucial for 
the development and maintenance of a malignant phenotype 
[17-19]. Moreover, it is known that the E6 and E7 proteins 
of different HPV types have different oncogenic potential. 
Concerning HPV mRNA, one study performing HPV 16, 18, 
31, and 33 mRNA detection using ISH and 
125I-labelled ri-
boprobes, reports an increased age at diagnosis and an in-
creased mortality associated with cervical carcinomas nega-
tive for HPV mRNA [3, 6, 7]. 
  In addition to the presence of HPV oncoproteins, integra-
tion of HPV DNA into the host genome is associated with 
the development of cervical cancer. As a result of HPV inte-
gration, expression of the HPV E6/E7 oncoproteins in-
creases, abrogating cell cycle control and apoptosis mecha-
nisms [20]. Alternatively to the integrated form, HPV can be 
found as episomes alone or in a mixed form containing both Human Papillomavirus and Survival  The Open Virology Journal, 2008, Volume 2    75 
episomal and integrated virus. According to Cooper et al. 
[21] and Kristiansen et al. [22], the physical state of HPV 
DNA can be determined by the pattern of the ISH signals. 
These authors observed that ISH signals may be spread over 
the entire nucleus (diffuse), indicating the episomal form, 
concentrated in small spots (punctuate), indicating the inte-
grated form, or in a mixture of the two, indicating both epi-
somal and integrated forms. Previously, it has been sug-
gested that the viral integration status may be important as a 
prognostic marker in cervical carcinomas, reported by two 
studies comparing the physical state of HPV by ISH and 
clinical outcome [23, 24]. However, in these studies, only 47 
and 50 women with cervical carcinoma were included [23, 
24] and thus, additional studies should be performed in order 
to reveal whether integration, as detected by ISH, can be 
used as a prognostic marker for the clinical outcome of car-
cinomas. 
  In a previous study, we have investigated the prevalence 
of HPV DNA and E6/E7 mRNA in a series of cervical 
squamous cell carcinomas (SCCs) using different PCR tech-
niques, ISH, nucleic acid sequence based amplification 
(NASBA), and the NASBA based PreTect HPV-Proofer 
assay [25]. The aim of the present study was to assess 
whether the presence of HPV DNA and/or HPV E6/E7 
mRNA, the presence of certain HPV genotypes or the physi-
cal state of HPV DNA, might have prognostic significance. 
To our knowledge, the present study is the first to report the 
association between HPV E6/E7 mRNA, detected by 
NASBA, and clinical outcome of women treated for SCCs. 
MATERIALS AND METHODOLOGY 
  Tumour material. From the original 204 cervical SCCs, 
FIGO stage Ia-IVb, included in our previous study [25], 202 
were included in the present analysis; for two women, clini-
cal information was not available. Staging was done accord-
ing to the FIGO guidelines [26]. All patients were treated at 
the Department of Gynaecologic Oncology, The Norwegian 
Radium Hospital, during the period 1995-1998. The median 
age was 54.1 years, ranging from 26 to 92 years. Patient in-
formation is listed in Table 1. Out of 58 patients with FIGO 
stage I, 13 were treated with radiation and 45 were treated by 
radical hysterectomy and pelvic lymphadenectomy. Postop-
erative adjuvant treatment was given to 17 of these patients. 
Of the patients with FIGO stage II-IV, 121 were treated with 
radiation, two with chemotheraphy and radiation, 14 with 
palliative radiotherapy, two with radical hysterectomy and 
pelvic lymphadenectomy and five had palliative treatment. 
After treatment, patients were followed up at The Norwegian 
Radium Hospital or at local hospitals. One patient was lost to 
follow-up after 3 months; all the others were followed until 
death or until August 2006. A total of 79 (39.1%) patients 
suffered a relapse and 75 (37.1%) died of cervical cancer. 
For patients still alive, median follow-up was 117 months 
(range from 92 to 139 months). Median follow-up for pa-
tients without relapse was 115 months (range from 76 to 138 
months). 
  Fresh frozen tissue, taken from the primary tumour at the 
time of diagnosis and stored at -70
oC, was used for PCR and 
NASBA analyses. For ISH, formalin-fixed, paraffin-
embedded tissue from the same tumours was used. 
  The study has been approved by The Regional Commit-
tee for Medical Research Ethics South of Norway (S-
06381a), The Social- and Health Directorate (06/4509 and 
06/4417), and The Data Inspectorate (06/01467-3). 
  HPV DNA analysis by PCR. Type-specific PCR, identi-
fying HPV 16, 18, 31, 33, 35, 45, 52 and 58 DNA, was per-
formed as described previously [25]. HPV DNA detection 
was also performed by consensus Gp5+/6+ PCR as described 
previously [25]. Samples negative by type-specific PCR 
were tested by the Gp5+/6+ enzyme immunoassay (EIA) and 
reverse line blot (RLB) assay [27]. 
  HPV DNA analysis by ISH. ISH was carried out with 
biotinylated probes against HPV 16 and 18 (gifts from profs. 
Harald zur Hausen and Ethel-Michele de Villiers, Germany) 
[28, 29] and HPV 31 and 33 (Eurodiagnostics BV) and an 
alkaline phosphatase anti-alkaline phosphatase detection 
system, as described previously [25]. The physical state of 
HPV DNA was determined by the pattern of the ISH signal 
as described in Cooper et al. [21] and Kristiansen et al. [22]: 
A diffuse signal indicates episomal DNA, a punctuate signal 
indicates integrated DNA and a mixture of these two patterns 
indicates the presence of both episomal and integrated DNA. 
Table 1.  HPV Detection in Relation to Method and Clinico-Pathological Variables 
 
Variables   No. of Cases  NASBA
1 HPV Positive (%)  Type-Specific PCR
2 HPV Positive (%)  ISH
3 HPV Positive (%) 
 Age  
 50  85  83 (97.6)  81 (95.3)  69 (81.2) 
51-70  67  59 (88.0)  61 (91.0)  51 (76.2) 
>70  50  44 (88.0)  44 (88.0)  38 (76.0) 
FIGO  
I (IA-IB)  58  54 (93.1)  54 (93.1)  46 (79.3) 
II (IIA-IIB)  82  77 (93.9)  76 (92.7)  63 (76.8) 
III (IIIA-IIIB)  40  34 (85.0)  35 (87.5)  32 (80.0) 
IV (IVA-IVB)  22  21 (95.5)  21 (95.5)  17 (77.3) 
1NASBA: Nucleic acid sequence based amplification; HPV 16, 18, 31, 33, 35, 45, 52, and 58 E6/E7 mRNA [25]. 
2PCR: Polymerase chain reaction; HPV 16, 18, 31, 33, 35, 45, 52, and 58 DNA [25]. 
3ISH: In situ hybridization; HPV 16, 18, 31 and 33 DNA [25]. 76    The Open Virology Journal, 2008, Volume 2  Holm et al. 
  HPV E6/E7 mRNA analysis by NASBA. The real-time 
multiplex NASBA assay, including PreTect
TM HPV-Proofer, 
identifying HPV 16, 18, 31, 33, 35, 45, 52 and 58 E6/E7 
mRNA, was performed as suggested by the manufacturer 
(NorChip AS, Klokkarstua, Norway) and as published previ-
ously [25, 30]. 
  TP53 mutation analysis.  TP53 mutation analysis was 
performed in tumour DNA by resequencing exon 2-11 using 
the 3730 DNA Analyzer (Applied Biosystems, Applied Bio-
systems, Foster City, California, USA). All fragments were 
sequenced in both directions and the primers used were 
linked to universal M13 sequences in the 5’ position to sim-
plify the sequencing reaction (Table 2). 25 ng DNA was am-
plified in a 10 μl PCR reaction using HotStarTaq DNA Po-
lymerase (Qiagen) and touchdown PCR with annealing tem-
peratures moving from 68°C to 56°C. SeqScape
® Software 
v2.5 (Applied Biosystems) was used for alignment to refer-
ence sequence and the scoring were carried out by two expe-
rienced operators independently. GeneBank accession num-
ber NM_000546 was used as reference sequence. 
 
  Statistical analysis. For statistical evaluation and based 
on previous studies [2, 7, 9, 13, 15, 23], the cases were di-
vided into different groups. Furthermore, the different HPV 
detection methods were evaluated either individually and/or 
collectively (Table 3). 
  The concordance between the different methods was 
evaluated by McNemar test. Differences in proportions were 
evaluated by the Person 
2 test. Survival was calculated by 
the method described by Kaplan and Meier and comparisons 
performed by the log-rank test. Progression free survival 
(PFS) was defined as the interval between diagnosis and 
relapse of cervical cancer and disease specific survival 
(DSS) as the interval between diagnosis and cervical cancer 
related death. A Cox proportional hazards regression model 
was used for both univariate and multivariate evaluation of 
survival rates. In the multivariate analysis, forward and 
backward stepwise regression was used. All calculations 
were performed using the SPSS 15.0 statistical software 
package (SPSS, Chicago, IL). A p  < 0.05 was considered 
statistical significant. 
Table 2.  TP53 Gene Sequencing Primers 
 
Exons  Forward Primer (5’)  Reverse Primer (3’)  PCR Fragment Length (bp) 
2,3 
aGGAGTGCTTGGGTTGTGGT 
bCGGCAAGGGGGACTGTA  586 
4 
aGACTTCCTGAAAACAACG 
bCACACATTAAGTGGGTAAAC  593 
5,6 
aTTT CTT TGC TGC CGT CTTC 
bTTG CAC ATC TCA TGG GGT TA  588 
7 
aGAC CAT CCT GGC TAA CGG 
bCAC AGG TTA AGA GGT CCC AAA  595 
8,9 
aTTT GGG ACC TCT TAA CCT GT 
bCAG GCA AAG TCA TAG AAC CAT  733 
10 
aCAT GTT GCT TTT GTA CCG TC 
bGGC AAG AAT GTG GTT ATA GGA   396 
11 
aAAG GGA AGA TTA CGA GACT 
bTAA GCT GGT ATG TCC TAC TC  500 
All primers are linked to universal M13 sequences in the 5` position: 
aM13F: TGT AAA ACG ACG GCC AGT (forward). 
bM13R: CAG GAA ACA GCT ATG ACC (reverse). 
 
 
Table 3.  Groups for Statistical Evaluation. The Different HPV Detection Methods were Evaluated Either Individually (I) and/or 
Collectively (C) 
 
1  High-risk HPV positive vs high-risk HPV negative  I + C 
2 HPV  16  vs HPV 18 vs other HPV types vs multiple HPV vs HPV negative  I + C 
3 HPV  16  vs all other HPV positives and negatives  I + C 
4 HPV  18  vs all other HPV positives and negatives  I + C 
5 HPV  16/18  vs all other HPV positives and negatives  I + C 
6 HPV  16  vs HPV 18  I + C 
7 HPV  16  vs HPV 18 vs all other HPV positives and negatives  I + C 
8 High-risk  HPV  vs HPV 6, 26, 66, 69, 73 vs HPV negative  C 
9  HPV 6, 26, 66, 69, 73 vs HPV negative  C 
10 Single  vs multiple infections  C 
11  HPV punctuate signal vs HPV punctuate/diffuse signal vs HPV negative  I (ISH) 
12  HPV 16 punctuate signal vs HPV 16 punctuate/diffuse signal vs HPV 16 negative.   I (ISH) 
High-risk HPV = HPV 16, 18, 31, 33, 35, 45, 52 and 58. 
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RESULTS 
  In total, 196 of the 202 (97%) samples have previously 
been found to harbour an HPV infection [25]. By type-
specific PCR, high-risk HPV (types 16, 18, 31, 33, 35, 45, 52 
and 58) DNA has previously been detected in 186 of the 202 
(92.1%) samples. By NASBA, high-risk HPV (types 16, 18, 
31, 33, 35, 45, 52 and 58) E6/E7 mRNA was detected in 186 
of the 202 (92.1%) samples. The results for these two meth-
ods were similar (p = 1.00) (Table 4), with divergence in 
only 4 cases, as two of the cases positive by type-specific 
PCR (HPV 16 and 33) were negative for HPV E6/E7 mRNA 
(case 3307 and 3959), and two cases positive for HPV E6/E7 
mRNA (HPV 31 and 45) were negative by type-specific 
PCR [25]. It is important to notice, that sample 3307 and 
3959 originally were negative by all methods and became 
positive by type-specific PCR only when tested on 10 times 
more concentrated material (nevertheless remaining RNA 
negative). The quality of the RNA within the sample was not 
investigated at the time of HPV detection as NASBA in gen-
eral was performed successfully as shown by detectable 
mRNA expressed from the housekeeping gene U1A. The 
positivity rate for NASBA and type-specific PCR is pre-
sented in Table 1. Out of 16 cases testing negative by type-
specific PCR and NASBA, seven cases were previously 
found to be positive for another HPV type (HPV 6, 26, 66, 
69, and 73) by consensus Gp5+/6+ PCR and RLB [25]. 
Moreover, one additional HPV 18 infection was found by 
RLB and ISH. 
Table 4.  Association Between HPV DNA and mRNA 
 
Type-Specific PCR
2 
NASBA
1 
HPV Negative  HPV Positive  Total 
HPV negative  14  2  16 
HPV positive  2  184 186 
Total 16  186  202 
1NASBA: Nucleic acid sequence based amplification; HPV 16, 18, 31, 33, 35, 45, 52, 
and 58 E6/E7 mRNA [25]. 
2PCR: Polymerase chain reaction; HPV 16, 18, 31, 33, 35, 45, 52, and 58 DNA [25]. 
 
  ISH detected HPV 16, 18, 31 and 33 DNA in 158 of the 
202 (78.2%) samples (Table 1). Detailed results have been 
presented previously [25]. The physical state of HPV DNA 
was determined by the pattern of the ISH signal. In 84 
(53.2%) of samples a punctuate signal, indicating integrated 
virus DNA was seen, in 74 (46.8%) samples both diffuse and 
punctuate signals indicating both integrated and episomal 
viral DNA were seen, while none of the samples had only 
diffuse signal indicative of episomal viral DNA only. 
  Mutation analyses of the TP53 gene revealed mutations 
in 3 of the 6 HPV negative samples (50%) (Table 5). 
  HPV of any type tended to be detected less frequently by 
increasing age of the patients. This trend obtained statistical 
significance for high-risk HPV (group no. 1, Table 3) when 
based on results obtained with NASBA (p = 0.04) and all 
methods collectively (p = 0.03). In line with this, absence of 
HPV 16/18 with all methods (group no. 5, Table 3) was sig-
nificantly correlated with higher age (p = 0.03). No correla-
tion was found to FIGO stage. 
  FIGO stage was a strong indicator of survival in both 
univariate and multivariate analysis as shown in Table 6. 
Age was of statistical significance in univariate but not in the 
multivariate analysis. 
  Based on the HPV E6/E7 mRNA (NASBA) results, pa-
tients testing negative had a statistically significant poorer 
DSS in univariate analysis than those testing positive, as 
shown in Fig. (1) (p = 0.03), while the difference in PFS did 
not obtain statistical significance (p = 0.10). Comparing 
high-risk HPV vs HPV 6, 26, 66, 69 and 73 vs HPV negative 
(group no. 8, Table 3, all methods collectively) HPV nega-
tive cases had a statistically significant poorer DSS in uni-
variate analysis that the two other groups (p = 0.03) (Fig. 2), 
whereas no statistical significance was seen for PFS (p = 
0.18). For the multivariate analysis, we combined the HPV 
high-risk group with the HPV 6, 26, 66, 69, 73 group be-
cause women in these categories were found to be of similar 
risk. In the multivariate analysis of DSS (Table 6), the high-
risk HPV E6/E7 mRNA (NASBA) and HPV high-risk/HPV 
6, 26, 66, 69, 73 (all methods collectively) negative status 
obtained independent significance. The differences in both 
PFS and DSS became smaller when based on the results 
from the other groups and methods for HPV detection and 
was not of statistical significance. 
DISCUSSION 
  In this study, we have investigated the relation of the 
presence of HPV DNA and/or HPV E6/E7 mRNA, as well 
as the physical state of HPV DNA, with the clinical outcome 
of 202 women treated for cervical SCC. We were particu-
larly interested in comparing the physical state of HPV DNA 
detected by ISH, and HPV E6/E7 mRNA expression, de-
Table 5.  Mutation Analysis of the TP53 Gene in HPV Negative SCCs. 
 
Sample  TP53 Status  Affected Exon  Affected Codon  Codon Alteration  Amino Acid Alteration  HGVS Nomenclature 
3596 Mut  7  245  GGCAGC GlySer c.733G>A 
3655 Mut  5  177  CCCTCC ProSer c.529C>T 
3754 WT           
3951 WT           
3952 WT           
3957 Mut  5  141  TGCTGA CysStop c.423C>A 
Mut = Mutation. 
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tected by NASBA, with clinical outcome. Only two studies 
have previously compared the physical state of HPV DNA, 
detected by ISH, and clinical outcome [23, 24] and no study 
has this far investigated the association between HPV E6/E7 
mRNA detected by NASBA and prognosis. 
 
Fig. (1). Kaplan and Meier curves of DSS related to HPV E6/E7 
mRNA expression detected by NASBA. High-risk HPV E6/E7 
mRNA negative cases (n = 16) had a significantly worse DSS than 
those cases with detectable high-risk HPV E6/E7 mRNA (n = 186) 
(p = 0.03). The p-value differs slightly from that in Table 3 due to 
the use of the log-rank test as opposed to the Cox regression analy-
sis in Table 3. 
  Regarding the relation between HPV status and age, it 
has previously been reported that women with HPV DNA 
negative tumours were older than women with HPV DNA 
positive tumours [3, 4, 9]. In a study of Schwartz and col-
leagues [13], however, no association between HPV DNA 
data and age was demonstrated. Also, in some previous stud-
ies, infections with HPV 16 [10, 11], HPV 33/35 [2] and 
HPV types other than HPV 16/18 [11] have been found to 
increase with age, whereas in other studies, HPV 16 [2] and 
HPV 18 [11] infections were found to be frequent also in 
lower age groups. In the present study, high-risk HPV nega-
tives by NASBA, as well as HPV negatives by all methods, 
was significantly correlated with higher age. This was also 
the case for HPV 16/18 negatives based on all methods col-
lectively. In summary, such conflicting results may be ex-
plained by variation in terms of HPV detection methods, 
number and type of HPV types detected by the assay used, 
patient selection, or number of patients included in the dif-
ferent studies. 
 
Fig. (2). Kaplan and Meier curves of DSS related to the combina-
tion of high-risk HPV cases (n = 189) vs HPV 6, 26, 66, 69 and 73 
cases (n = 7) vs HPV negative cases (n = 6) (all methods collec-
tively). HPV negative cases had a significantly worse DSS than the 
two other groups (p = 0.03). 
  The differences in HPV status between the results ob-
tained by NASBA and type-specific PCR were small with 
discordance in only 4 of 202 samples (2%) and therefore, the 
clinical relevance is questionable. It is possible that the mi-
nor differences between type-specific PCR and NASBA may 
reflect accidental circumstances or poor sample quality, 
Table 6.  Cox Regression Analysis of Disease Specific Survival (DSS) and Progression Free Survival (PFS) 
 
Univariate Analysis  Multivariate Analysis 
Variables 
HR
a 95%CI 
b  p HR 
a 95%CI 
b  p 
DSS 
 FIGO stage  2.2  1.72-2.74  <0.001  2.22  1.75-2.81  <0.001 
 Age group  1.7  1.30-2.27  <0.001       
 Collective (HPV HR vs HPV X vs HPV neg)
c  1.7 1.05-2.82  0.03  3.24  1.14-9.19  0.03 
 NASBA (HPV HR pos vs HPV HR neg)  2.1  1.05-4.28  0.04  2.42  1.20-4.88  0.01 
PFS 
 FIGO stage  2.1  1.68-2.66  <0.001  2.11  1.68-2.66  <0.001 
 Age group  1.4  1.10-1.90  0.008       
aHazard risk. 
b95% confidence interval of the hazard risk. 
HR = high-risk HPV 16, 18, 31, 33, 35, 45, 52 and 58. 
X = HPV 6, 26, 66, 69 and 73. 
cIn the multivariate analysis two groups HPV HR/X vs HPV neg were tested. 
Pos = positive; neg = negative. Human Papillomavirus and Survival  The Open Virology Journal, 2008, Volume 2    79 
rather than the actual absence of HPV DNA or mRNA in the 
respective samples. This is supported by the fact that the 
samples 3307 and 3959 became positive by type-specific 
PCR only when tested on 10 times more concentrated mate-
rial. Furthermore, we cannot exclude the possibility that 
these differences may be explained by a possible degradation 
of HPV mRNA, for example in case of suboptimal freezing 
procedures for the tissue directly following the operation of 
the patient. On the other hand, we cannot either exclude that 
the differences actually reflect a higher amount of DNA pre-
sent as compared to E6/E7 mRNA, and vice versa, as may be 
seen for example in relation to the integrated form of the 
virus: Several viral copies may be integrated as concatemers 
in the human genome; however, expression of the viral on-
cogenes may be silenced by host regulatory mechanisms. 
Yet, since the E6 and E7 proteins are shown to be necessary 
for malignancy, this situation is questionable. Alternatively, 
only one or two viral copies may be integrated, exerting a 
high level of E6/E7 expression, explaining the DNA nega-
tive/mRNA positive result; the negative DNA result may 
therefore be explained by low analytical sensitivity of the 
PCR method. Another explanation for the different results by 
the two methods might be mutations or deletions in the HPV 
target sequences. Deletions of larger regions of the HPV 
genome can be seen for example upon chromosomal integra-
tion, with the interruption within the E1 or E2 gene and the 
possible deletion of downstream sequences as the E5, L2, 
and L1 genes. 
  The survival analysis of our data suggests that patients 
negative for high-risk HPV (types 16, 18, 31, 33, 35, 45, 52 
and 58) E6/E7 mRNA (NASBA) or negative for HPV high-
risk/HPV 6, 26, 66, 69 and 73 (all methods collectively) had 
a poorer DSS than patients positive for these HPV groups. 
This is in accordance with the data of Higgins et al. [3] in-
vestigating HPV 16, 18, 31 and 33 mRNA expression using 
ISH and 
125I-labelled riboprobes and the work of DeBritton 
et al. [4] identifying HPV 16, 18 and 33 using PCR, South-
ern blot and slot blot techniques. However, possible underly-
ing biological mechanisms of this phenomenon remain to be 
elucidated. One possible explanation may be related to HPV 
unrelated genetic aberrations. We have previously found that 
in HPV negative cervical carcinomas, compared to HPV 
positive cases, TP53 mutations are frequently identified [31], 
which results in lack of functional p53 protein and a possibly 
more aggressive tumour. This is supported by this study, 
where we show that 3 of 6 (50%) of the HPV negative cases 
had TP53 mutations. In general, in cervical carcinomas lack-
ing HPV E6/E7 mRNA expression (or in which the onco-
genic expression is kept low), also additional molecular ab-
errations may exist that increase the carcinogenic potential 
and aggressiveness of the tumour or which may decrease the 
sensitivity to radiation therapy. In other words, other pro-
gression factors than the action of the E6/E7 oncoproteins 
may in a small number of cases play a more important role at 
a later stage in the progression of cancer. It should also be 
mentioned that the number of cases negative for HPV was 
low and the results have to be confirmed in larger studies. 
  Based on the results of PCR and ISH, the presence of 
HPV DNA was not found to be a prognostic factor in cervi-
cal SCCs. Similar findings have been reported by others [7-
10]. However, these observations in turn contradict other 
investigations; using multivariate analysis, Riou et al. [2] 
and deBritton et al. [4] reported that patients negative for 
HPV DNA had a poorer prognosis than patients positive for 
HPV DNA. These conflicting results may be due to the small 
number of negative cases included and additional studies are 
needed in order to reveal whether the detection of HPV by a 
specific method may be of prognostic value in assessing sur-
vival. 
  When it comes to the individual HPV types, reduced sur-
vival has in particular been correlated with HPV 18 positive 
tumours [11-15]. Our results, however, show that neither 
HPV 18 DNA nor HPV 18 E6/E7 mRNA had any correla-
tion to clinical outcome. Also, it is known that adenocarci-
nomas have a higher prevalence of HPV 18 than SCCs [12-
15] and for patients with advanced adenocarcinoma, a sig-
nificantly worse prognosis has been reported [32]. The dif-
ferences may therefore be explained by the fact that our se-
ries consisted of SCCs only, whereas in the other studies 
both SCCs, adenocarcinomas and adenosquamous carcino-
mas were included [11-15]. Reduced survival has also been 
demonstrated for women with multiple HPV types. Our re-
sults show no correlation of multiple types with clinical out-
come. 
  In addition to specific HPV types, HPV DNA integration 
status has also been suggested to play a role for the clinical 
outcome of cervical SCCs. In the present study, integrated 
HPV was detected by ISH; however did not correlate with 
either DSS or PFS free survival. Previously, only one re-
search group has used ISH to compare the physical state of 
HPV and clinical outcome for patients with cervical carci-
noma [23, 24]. In these studies, including 47 and 50 patients 
respectively, PFS was shorter for the women with tumours 
containing integrated HPV DNA than for the women with 
tumours containing episomal or episomal/integrated HPV 
DNA [23, 24]. In two studies using the E2/E6 ratio PCR 
assay for determining the integration status (based on the 
fact that E2 is generally disrupted upon integration [33]), 
including 50 and 158 patients respectively, it was reported 
that viral integration was significantly associated with de-
creased PFS [24, 34]. Another study including 40 patients, 
reported that HPV 16 positive tumours with a disrupted E2 
gene had a tendency towards a shorter progression free sur-
vival [35]. In contrast to these studies, but in agreement with 
our data, Szarka et al. [36] used southern blot hybridization 
and E1/E2 vs E6 specific PCR on a series of 41 cervical can-
cers and found that HPV 16 integration did not correlate with 
progression free survival. One explanation for the discrep-
ancy of previous results [23, 24, 35, 36] may be the small 
number of patients investigated, or may possibly also be re-
lated to differences in terms of the detection assays. In gen-
eral, the clinical outcome and values of prognostic signifi-
cance are obviously strongly associated with the method 
used and also with the number of and specific types included 
in the assay. 
CONCLUSION 
  The presence of high-risk HPV DNA (types 16, 18, 31, 
33, 35, 45, 52 and 58), as well as the physical state of the 
virus, was not significantly associated with clinical outcome. 
Moreover, no differences in survival of women harbouring 
specific HPV types were seen. Concerning high-risk HPV 
E6/E7 mRNA (detected by NASBA) and HPV high-80    The Open Virology Journal, 2008, Volume 2  Holm et al. 
risk/HPV 6, 26, 66, 69 and 73 (all methods collectively), 
absence may appear to be associated with poor DSS; how-
ever, due to the low number of cases negative for HPV, the 
results should be confirmed in larger studies. To our point of 
view, in order to better consider the prognosis of women 
with cervical carcinoma, a better delineation of the total ge-
netic changes (including among others TP53 mutations), not 
only the HPV status, would be necessary. 
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